Last $51.46 USD
Change Today +0.11 / 0.21%
Volume 418.1K
DXCM On Other Exchanges
DXCM is not on other exchanges.
As of 5:10 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

dexcom inc (DXCM) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/13/14 - $54.50
52 Week Low
05/2/14 - $28.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DEXCOM INC (DXCM)

dexcom inc (DXCM) Related Businessweek News

No Related Businessweek News Found

dexcom inc (DXCM) Details

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. It offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. The company’s ambulatory product line includes SEVEN PLUS, DexCom G4 system, and DexCom G4 PLATINUM system for adults with diabetes to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia, and to facilitate acute and long-term therapy adjustments, as well as DexCom SHARE, a remote monitoring system, which provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring. Its in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. The company also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. It markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. The company was founded in 1999 and is headquartered in San Diego, California.

646 Employees
Last Reported Date: 02/20/14
Founded in 1999

dexcom inc (DXCM) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $420.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $325.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $237.0K
Chief Technical Officer
Total Annual Compensation: $284.9K
Executive Vice President of Strategy & Corpor...
Total Annual Compensation: $284.9K
Compensation as of Fiscal Year 2013.

dexcom inc (DXCM) Key Developments

DexCom, Inc. Amends and Restates Bylaws

On November 21, 2014, the Board of Directors of DexCom, Inc. approved and adopted amendments to company's Amended and Restated Bylaws (the Bylaws) principally to add a new provision for the election, at the option of the Board, of a Lead Independent Director who is independent pursuant to the rules of The NASDAQ Stock Market and specify that the Lead Independent Director may (1) preside at meetings of stockholders in the Chairperson of the Board's absence, (2) preside at the meetings of the Board in the Chairman of the Board's absence or at the Chairman of the Board's request and (3) call special meetings of the Board. These amendments to the Bylaws were effective upon approval by the Board.

DexCom Announces Appointment of Mark G. Foletta as Board Member

DexCom, Inc. announced the appointment of Mark G. Foletta as an independent Board member of the company. Mr. Foletta currently serves on the board of directors of AMN Healthcare Services and Regulus Therapeutics. Previously, Mr. Foletta served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc. from 2006 to August 2012 during the growth of Amylin's diabetes and obesity franchises, including the commercial launch of diabetes drugs BYDUREON(R), BYETTA(R) and SYMLIN(R).

DexCom, Inc. Provides Revenue Guidance for the Year 2014

DexCom, Inc. announced that it expects product revenue for the full year 2014 to meet or exceed the top end of range of $235 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DXCM:US $51.46 USD +0.11

DXCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Insulet Corp $46.59 USD +0.26
Merge Healthcare Inc $3.14 USD -0.04
NeuStar Inc $27.25 USD -0.18
Radview Software Ltd $0.0025 USD 0.00
Tandem Diabetes Care Inc $14.13 USD -0.22
View Industry Companies

Industry Analysis


Industry Average

Valuation DXCM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 17.2x
Price/Book 34.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEXCOM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at